Background: To prospectively determine the feasibility of sentinel lymph node biopsy (SLNB) in preoperatively diagnosed multiple unilateral synchronous invasive breast cancers.
introduction
Since the first reports of sentinel lymph node biopsy (SLNB) by Krag et al. and Giuliano et al. [1, 2] , SLNB as proven to be a feasible procedure to replace axillary lymph node dissection (ALND), with a high degree of accuracy, a low false-negative rate (FNR), low morbidity, and a low axillary relapse [3] [4] [5] [6] . However, application of SLNB has been limited to unifocal breast cancer, and patients with multifocal or multicentric disease are usually excluded from studies. In 2005, the American Society of Clinical Oncology (ASCO) conducted a systemic review of SLNB and indicated that SLNB can be applied and identified in multicentric breast cancer through intradermal, subdermal, or subareolar injection techniques, but with limited level of evidence [7] .
Several clinical and anatomical criteria have been proposed to identify multifocal and multicentric cancers, including the distance between cancer foci, the presence of histological normal tissue among nodules, and the location in the same or different quadrants of the breast. In fact, multicentric and multifocal cancers should be defined as a multiple synchronous tumors (MSTs) in the same breast and the practical problem was the moment of diagnosis before surgery, during initial clinical and radiological evaluation, or after surgery, on pathological examination.
Several small retrospective or prospective studies, including preoperative or postoperative or both MST, have indicated that the test performance of SLNB is similar to that for women with unifocal disease. Designed as a French multi-institutional trial, the purpose of this prospective study was to evaluate the feasibility and accuracy of SLNB in preoperative diagnosed invasive MST.
patients and methods
The Interest of Axillary Sentinel Lymph Node Biopsy in Multiple Invasive Breast Cancer (IGASSU) study was validated by scientific and ethical boards as a prospective multi-institutional study with initial breast surgery, SLNB, and level I-II ALND in synchronous and ipsilateral multiple invasive breast carcinoma. Written informed consent was obtained from all patients. Each center had undertaken to validate their SLNB learning curves beforehand.
Patients eligible for the IGASSU study had an operable invasive MST. MST was defined as two or more physically separate invasive tumors in the same or different breast quadrants. MST was suspected from clinical and radiological findings (i.e. mammography and sonography were carried out in all patients, magnetic resonance imaging was optional). The diagnosis of invasive MST was confirmed histologically in all patients by core needle biopsy before surgery.
The IGASSU study was proposed to all patients with MST eligible for initial breast surgery (radical modified mastectomy or conservative surgery if MST was limited to two foci in the same quadrant and patient's opposition for total mastectomy).
Exclusion parameters were noninfiltrative carcinoma, inflammatory cancer, clinical axillary lymph node (N1), previous breast surgery or oncologic treatment, MST only diagnosed on pathological examination after breast surgery, pregnancy.
lymphatic mapping technique
For lymphatic mapping, either vital blue dye (Patent Blue V sodique 2.5%; Guerbet, Roissy, France), 2 ml, or rhenium sulfide colloids Tc 99m (Nanocis kit; CIS Bio International, Gif sur Yvette, France), 30-40 MBq, alone or combination of blue dye and radiocolloid were used, left to the discretion of the participating surgeons. Injection sites were subareolar.
Intraoperatively, the sentinel node (SN) was identified by retrieving hot nodes using a handheld gamma probe and/or blue-staining lymph nodes. After SLNB, all patients underwent a level I-II lymph node dissection.
pathological analysis
No intraoperative pathological examination was carried out. Sentinel lymph nodes (SLNs) were submitted by the surgeons separately from the rest of the ALND.
Each node (sentinel and nonsentinel) was serially sectioned and totally embedded in paraffin. SLNs were cut into six sections at 150-lm intervals.
Standard staining was carried out on three levels, and immunohistochemical labeling was carried out at the three intermediary levels in absence of metastatic disease detected on these first sections. The nonsentinel lymph nodes obtained by lymph node dissection were totally included with 4-lm section cuts from each block and stained with hematein phlostin safron. No immunohistochemical labeling was carried out for the nonsentinel nodes.
The microscopic reporting stated the number of axillary SLNs, the total number of nodes (sentinel and nonsentinel), and the number of nodes containing macrometastasis (>2 mm), micrometastasis (0.2-2 mm), and isolated cells (<0.2 mm), using the definition of the American Joint Committee on the Cancer Staging System.
Every mastectomy specimen was fixed in 10% formaldehyde solution, placed oriented, and serially sectioned at 1.0 cm intervals. Representative suspicious lesions, either by palpation or on image, were identified according to their numbers and were measured, embedded in tissue blocks, for histological examination. Tumor size was measured as the maximal invasive component of the main primary tumor on histology.
statistical considerations
Assuming that the FNR is 10%, we had calculated that a sample size of 139 patients provides a precision of 65% for the measured FNR.
Continuous variables were compared by Student's t-test. For comparison of categorical variables, Fisher's exact test was used. All reported P values are results of two-sided tests. A P value £0.05 was considered statistically significant.
The identification rate was defined as the ratio of the number of patients with at least one detected SLN (blue, radiocolloid, or both) to the total number of patients. The performance of SLNB was established in comparison with the histologic status of lymph node (pN) status. The performance of SLNB had been estimated with accuracy (A) = (true positive + true negative)/ (total patients with at least one detected SLN), sensitivity (Se) = (true positive)/(true positive + false negative), and negative predictive value (NPV) = (true negative)/(true negative + false negative). The FNR was defined as the ratio of the number of patients with a false-negative case of SLNB to the number of patients with at least one involved node (macrometastasis, micrometastasis, or isolated cells), SLN or not, among patients with at least one detected SLN (false negative)/(true positive + false negative). A, Se, NPV, FNR and their 95% confidence intervals (95% CIs) were calculated from a classical 2 · 2 contingency table. A univariate analysis using odds ratio calculation was carried out to identify the risk factors for false-negative results. For this, we have compared the characteristics of patients with false-negative results and those of patients with true-negative results. participating surgical unit, 50% of the patients were included by three centers). Of these patients, 211 were suitable for evaluations (secondary refusal of the patient in four cases, no surgery in one case). The mean age of the study population was 55.9 years (611.4 years), and the median age was 55.6 years (range 32.5-79.3 years). Detailed patient and tumor characteristics are shown in Table 1 . The mean and median size of the largest ultrasonographic tumor was 15 mm (67 mm, range 4-50 mm). Technical characteristics of lymphatic mapping techniques are shown in Table 2 .
SLN detection rate
A SLN was successfully identified in 197 of the 211 patients [identified rate (IR) 93.4%]. Among patients with nonidentified SLN (n = 14), 11 patients had an involved ALND (7 with >3 positive nodes). A mean number of 2.2 SLN (range 1-8, 61.4) was successfully excised. The mean number of nodes in ALND was 12 (range 4-39, 65.7).
SLN pathological results and performance of SLN
The average rate of patients with at least one involved node [pN1, pN1 (mi+), or pN0 (i+)], sentinel or not, was 54% [114 of 211; 52% (103 of 197) among patients with identified SLN]. Among patients with an involved SN, at least another involved node was found in ALND in 45 cases (45 of 89, 50.5%). For the 108 patients without involved SN, at least an involved node was found in ALND in 14 cases (Figure 1 ). The FNR was 13.6% (95% CI 7% to 20%) (14 of 103), Se was 86.4% (89 of 103) (95% CI 79% to 93%), NPV was 87% (94 of 108) (95% CI 80% to 93%), and A was 92.9% (183 of 197) (95% CI 89% to 96%).
For the 14 patients with false-negative SN, 6 of these had one involved node in ALND, 6 had two involved nodes in ALND, and 2 patients with three involved nodes in ALND. The extent of lymph node involvement appeared to influence the risk of falsenegative results: 0 patient with ‡4N+/14 false-negative SLNB, 30 patients with ‡4N+/80 true-positive SLNB (P = 0.002).
For the 89 patients with involved SN, 54 (61%) had macrometastasis (48% with involved ALND), 24 
discussion
Consensus statements have been developed by some professional societies and conclude that SLNB could replace routine ALND for patients with unifocal invasive breast cancer [7] [8] [9] [10] . Should the SLNB be extended in special circumstances like multiple (multicentric/multifocal in preoperative examination) tumors? Most studies of SLNB have excluded MST, considering tumors located in different quadrants were thought not to drain into the same lymph node [11, 12] . Evidence obtained in the last few years about the functional anatomy of the lymphatic drainage of the breast supports the theory that all quadrants of the breast drain into the same lymph node [13] [14] [15] .
The literature review identified retrospective or prospective studies in which the test performance of SLNB was evaluated in MST with respect to the results of ALND (systematic completion axillary dissection irrespective of the results of SLNB) (Table 4 ). In most of these studies, the SLNB appears to be an acceptably accurate method in MST, with a FNR £10%. With a FNR = 13.6%, our results did not confirm the previously published data.
To date, our series is the largest multi-institutional prospective study on SLNB with systematic ALND in multiple invasive breast cancer. This is the sole prospective study focused on the consistency of SLNB in MST. The two previous studies 
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accounting >100 patients are retrospectively extracted from a prospective data collection of SLNB whatever the indication [21, 25] . The high FNR observed in the present study could be explained in part by an unexpected proportion of N+. The ASCO guidelines [7] had so indicated the risk reduction in NPV with an increasing lymph node-positive rate in the population studied and required caution when applying the SLNB procedure in patients at considerably increased risk of lymph node-positive disease. But, the present lymph node-positive rate is 54%. This rate is comparable with literature data [21] .
For ASCO panel [7] , the strongest predictors of low FNR were team experience, the use of combined detection, and the proportion of patients for whom mapping is successful. In the present study, because all surgical teams had consistent expertise in breast cancer surgery and had completed their SLNB learning curves, we wonder that theses factors are not likely in cause. The techniques for lymphatic mapping are different in the different surgical teams, the choice depending on investigator preferences. As a consequence, two-thirds of the procedures were carried out with combined techniques. Nevertheless, there is no statistical difference in terms of IRs. At least, since the heterogeneity in terms of lymphatic mapping techniques, the observed IR is high (93.4%).
Under univariate analysis, the sole factor associated with higher FNR is the tumor location. The FNR is 22% for external tumors compared with 7% for other tumors. At least, the false negative is more frequent in case of minimal lymph node involvement (£3N+). In this case, during the surgical procedure, the risk of lacking lymph node detection is certainly higher. This could be amplified by the fact that study protocol implying systematic lymph node dissection and consequently the surgeons were perhaps less attentive with digital examination by axillary dissection. However, this attentive digital examination is highly recommended to reduce the FNR up to 4% [28] .
conclusion
Regarding the high rate of false negative, we did not recommend the SLNB in MST, even in case of small lesions. But this study did not explore the long-term risk-benefit balance between classical lymph node clearance and SLNB in such population. 
